TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

NCT01883219 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
Stem Cell Transplantation
Minimal Residual Disease

Interventions

DRUG: TKIs

Sponsor

Nanfang Hospital, Southern Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]